Table 1 Comparison of the clinicopathological characteristics between the intensivist and non-intensivist groups
From: Intensivist coverage and critically ill COVID-19 patient outcomes: a population-based cohort study
Variable | Intensivist group nā=ā2653 | Non-intensivist group nā=ā10,450 | P-value |
|---|---|---|---|
Age, year | 67 [52, 75] | 65 [51, 74] | <ā0.001 |
Male sex | 1607 (60.6) | 5808 (55.6) | <ā0.001 |
Having a job | 1460 (55.0) | 5813 (55.6) | 0.582 |
Household income level | Ā | Ā | 0.190 |
Ā Medical aid group | 253 (9.5) | 964 (9.2) | Ā |
Ā Q1 (lowest) | 488 (18.4) | 1869 (17.9) | Ā |
Ā Q2 | 457 (17.2) | 1874 (17.9) | Ā |
Ā Q3 | 523 (19.7) | 2256 (21.6) | Ā |
Ā Q4 (highest) | 907 (34.2) | 3373 (32.3) | Ā |
Ā Unknown | 25 (0.9) | 114 (1.1) | Ā |
Residence | Ā | Ā | <ā0.001 |
Ā Urban area | 1519 (57.3) | 5355 (51.2) | Ā |
Ā Rural area | 1134 (42.7) | 5095 (48.8) | Ā |
Type of infection route | Ā | Ā | <ā0.001 |
Ā Inflow from foreign countries | 36 (1.4) | 135 (1.3) | Ā |
Ā Contact with person-related inflow from foreign countries | 1 (0.0) | 4 (0.0) | Ā |
Ā Outbreak in hospitals or nursing care centers | 311 (11.7) | 1581 (15.1) | Ā |
Ā Outbreak in local communities | 322 (12.1) | 1216 (11.6) | Ā |
Ā Contact with a patient confirmed with patients | 722 (27.2) | 3163 (30.3) | Ā |
Ā Unknown | 1,261 (47.5) | 4351(41.6) | Ā |
Ā CCI, point | 5.5 [3.4, 6.4] | 5.8 [3.8, 6.6] | 0.020 |
Underlying disability | Ā | Ā | 0.166 |
Ā Severe | 208 (7.8) | 941 (9.0) | Ā |
Ā Mild to moderate | 284 (10.7) | 1099 (10.5) | Ā |
Hospital level group | Ā | Ā | <ā0.001 |
Ā A | 312 (11.8) | 4,158 (39.8) | Ā |
Ā B | 185 (7.0) | 529 (5.1) | Ā |
Ā C | 2,072 (78.1) | 5,137 (49.2) | Ā |
Ā D | 84 (3.2) | 626 (6.0) | Ā |
Total case volume of ICU admission due to COVID-19 | Ā | Ā | <ā0.001 |
Ā Q1:0ā150 | 1115 (42.0) | 2221 (21.3) | Ā |
Ā Q2:151ā257 | 660 (24.9) | 2632 (25.2) | Ā |
Ā Q3:258ā408 | 657 (24.8) | 2687 (25.7) | Ā |
Ā Q4:āā„ā409 | 221 (8.3) | 2910 (27.8) | Ā |
1st vaccination | 1559 (58.8) | 6824 (65.3) | <ā0.001 |
2nd vaccination | 1378 (51.9) | 6271 (60.0) | <ā0.001 |
3rd vaccination | 692 (26.1) | 3485 (33.3) | <ā0.001 |
WHO clinical progression scale | Ā | Ā | Ā |
Ā 1 point (no oxygen therapy) | 451 (17.1) | 1672 (16.0) | 0.215 |
Ā 2 points (oxygen by mask or nasal prongs) | 944 (35.6) | 3887 (37.2) | <ā0.001 |
Ā 3 points (oxygen by NIV or HFNC) | 565 (21.3) | 1818 (17.4) | <ā0.001 |
Ā 4 points (intubation and MV) | 384 (14.5) | 1285 (12.3) | <ā0.001 |
Ā 5 points (MV with vasopressor use) | 208 (7.8) | 1642 (15.7) | <ā0.001 |
Ā 6 points (MV and vasopressor use, dialysis or ECMO) | 101 (3.8) | 146 (1.4) | <ā0.001 |
Diagnosis of ARDS | 326 (12.3) | 741 (7.1) | <ā0.001 |
In-hospital mortality | 715 (27.0) | 1990 (19.0) | <ā0.001 |